Transcription Factors in Lung Cancer: Mechanisms and Future Perspectives
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 9002
Special Issue Editors
Interests: respiratory medicine; tumor biology; molecular oncology; lung carcinogenesis; transcription factors; cancer cell signaling
Interests: molecular medicine; cancer mechanobiology; regulation of gene expression; transcription factors in health and disease; epigenetics; signal transduction; mechanotransduction
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The management of lung cancer has undergone revolutionary changes in the last few years. Advancements in our understanding of the molecular underpinnings of lung cancer have allowed for the development of several targeted therapies and immunotherapies. Nevertheless, lung cancer is a highly heterogeneous disease and the development of resistance to current therapies leads to disease recurrence and poor prognosis.
Transcription factors are major proteins located at the bottleneck of signaling pathways, which orchestrate a multitude of physiological cellular processes, including proliferation, differentiation, apoptosis, self-renewal, and migration. When transcription factors are deregulated they can promote the initiation and development of different cancer types. Recent research has revealed the implication of aberrant transcription factors in the two major types of lung cancer, NSCLC and SCLC. Identifying which and how individual transcription factors with oncogenic or tumor-suppressive functions contribute to lung cancer will potentially result in the development of novel therapeutics that are able to prolong the survival of lung cancer patients. Transcription-factor-targeting drugs could also be combined with other targeted therapies, immune checkpoint inhibitors, or radiotherapy in a synergistic fashion or to overcome resistance to current therapies. Additionally, transcription factors may be utilized as prognostic and predictive biomarkers for the treatment of lung cancer.
Since transcription factors act in concert with other proteins, including different transcription factors, coactivators, and corepressors, research efforts should also be focused on elucidating these transcription factor networks in each lung cancer subtype. Computational models are essential to fulfill this complex task and will help to analyze the multiple interactions within these networks, offering valuable insights that could improve clinical outcomes in lung cancer.
In this Special Issue, experts will highlight the role of transcription factors in lung cancer, deciphering the molecular mechanisms by which transcription factors promote NSCLC and SCLC and exploring their potential as therapeutic targets and biomarkers.
Dr. Kostas A. Papavassiliou
Prof. Dr. Athanasios G. Papavassiliou
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- transcription factors
- lung cancer
- NSCLC SCLC
- targeting
- biomarkers
- tumor suppressors
- oncogenes
- transcription factor network
- computational models
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.